“Tential Shares Drop 8.3% on Nov 23: Market Shock, No Corporate Trigger”
Saluda Medical reports strong first‑year results, surpassing revenue guidance and expanding its Evoke® System after FDA approval and global EVA™ platform rollout.
2 minutes to read